{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:58:08Z","timestamp":1783421888973,"version":"3.54.6"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T00:00:00Z","timestamp":1433980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sigrid Juselius Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of the present study was to investigate the effects of the carboxylesterase 1 (CES1) c.428G\u2009&gt;\u2009A (p.G143E, rs71647871) single nucleotide variation (SNV) on the pharmacokinetics of quinapril and enalapril in a prospective genotype panel study in healthy volunteers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a fixed\u2010order crossover study, 10 healthy volunteers with the <jats:italic>CES1<\/jats:italic> c.428G\/A genotype and 12 with the c.428G\/G genotype ingested a single 10\u2009mg dose of quinapril and enalapril with a washout period of at least 1\u2009week. Plasma concentrations of quinapril and quinaprilat were measured for up to 24\u2009h and those of enalapril and enalaprilat for up to 48\u2009h. Their excretion into the urine was measured from 0\u2009h to 12\u2009h.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The area under the plasma concentration\u2013time curve from 0\u2009h to infinity (AUC<jats:sub>0\u2013\u221e<\/jats:sub>) of active enalaprilat was 20% lower in subjects with the <jats:italic>CES1<\/jats:italic> c.428G\/A genotype than in those with the c.428G\/G genotype (95% confidence interval of geometric mean ratio 0.64, 1.00; <jats:italic>P<\/jats:italic>\u2009=\u20090.049). The amount of enalaprilat excreted into the urine was 35% smaller in subjects with the <jats:italic>CES1<\/jats:italic> c.428G\/A genotype than in those with the c.428G\/G genotype (<jats:italic>P<\/jats:italic>\u2009=\u20090.044). The <jats:italic>CES1<\/jats:italic> genotype had no significant effect on the enalaprilat to enalapril AUC<jats:sub>0\u2013\u221e<\/jats:sub> ratio or on any other pharmacokinetic or pharmacodynamic parameters of enalapril or enalaprilat. The <jats:italic>CES1<\/jats:italic> genotype had no significant effect on the pharmacokinetic or pharmacodynamic parameters of quinapril.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The <jats:italic>CES1<\/jats:italic> c.428G\u2009&gt;\u2009A SNV decreased enalaprilat concentrations, probably by reducing the hydrolysis of enalapril, but had no observable effect on the pharmacokinetics of quinapril.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12667","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T10:30:25Z","timestamp":1430217025000},"page":"1131-1138","source":"Crossref","is-referenced-by-count":37,"title":["Effect of carboxylesterase 1 c.428G\u2009&gt;\u2009A single nucleotide variation on the pharmacokinetics of quinapril and enalapril"],"prefix":"10.1111","volume":"80","author":[{"given":"E. Katriina","family":"Tarkiainen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksi","family":"Tornio","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko T.","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Launiainen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00160a026"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198631030-00002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262020-00009"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331978904000403"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02601.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199325040-00003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331978904000404"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141030-00006"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.053512"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.20.869"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.257"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.084657"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2006.07.001"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.09.002"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.13"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32835aa8a2"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.08.014"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.12.017"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.28.719"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.04.015"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.201640"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024943"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100082"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.101"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.034454"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-12-RG-143"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.183"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.21.173"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.01.011"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002857"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.04.018"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328335c368"},{"key":"e_1_2_9_34_1","first-page":"1602","article-title":"Renin\u2013angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition","volume":"13","author":"Hingorani AD","year":"1995","journal-title":"J Hypertens"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04419.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2004.029"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2005.09.010"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12667","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:34:09Z","timestamp":1696311249000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/bcp.12667"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12667","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,11]]}}}